Ms Debroux is group chief financial officer, executive board member, of Heineken N.V., the Netherlands.
From 2010 to 2015, Ms Debroux held the position as group chief financial officer, executive board member, at JCDecaux SA, France. From 1996 to 2010, Ms Debroux held a number of positions at Sanofi Aventis SA (previously Synthelabo SA), including those of chief strategic officer, chief financial officer and deputy chief financial officer.
Prior to this, Ms Debroux held positions in corporate finance at Elf Aquitaine, France, from 1993 to 1996, as an analyst in Corporate Finance for Merrill Lynch, UK, from 1992 to 1993, and as a research analyst for Putnam, Hayes & Bartlett, USA, from 1989 to 1990.
Ms Debroux is member of the board of Exor N.V., the Netherlands, and of HEC Paris Business School, France.
Ms Debroux holds a Master Degree from HEC Paris, Ecoles des Hautes Etudes Commerciales, France, from 1992.
Ms Debroux was first elected to the Board of Novo Nordisk A/S in March 2019. Her term as a board member expires in March 2020.
In March 2019, the Board of Directors of Novo Nordisk A/S assessed that Ms Debroux is regarded as an independent board member as defined in Section 3.2.1 of the Recommendations on Corporate Governance designated by Nasdaq Copenhagen.
Ms Debroux is a female French national, born July 1969.